FDA Inspection Shortfall Highlighted By GAO Once Again
This article was originally published in The Gray Sheet
FDA's "risk-based" inspection policy for device manufacturers is identified by the General Accounting Office in a January report to Congress as one of the "major management challenges and program risks" facing HHS.
You may also be interested in...
Previous businesses FDA warned about COVID-19 claims for chlorine dioxide, a bleach solution, were marketing dietary supplements unlawfully. But Pro Breath MD's oral rinses available under the Dentist Select and OraCare brands are allowed and FDA isn’t asking the firm to discontinue distribution.
The Stark Law ban on self-referrals wouldn’t apply to some physician owners of advanced imaging facilities under a CMS final rule.
Pfizer’s abrocitinib and Biogen/Eisai’s aducanumab are among a host of new investigational products that are under review by the European Medicines Agency.